CO2017004994A2 - Análogos de urea unidos sustituidos como moduladores de sirtuina - Google Patents

Análogos de urea unidos sustituidos como moduladores de sirtuina

Info

Publication number
CO2017004994A2
CO2017004994A2 CONC2017/0004994A CO2017004994A CO2017004994A2 CO 2017004994 A2 CO2017004994 A2 CO 2017004994A2 CO 2017004994 A CO2017004994 A CO 2017004994A CO 2017004994 A2 CO2017004994 A2 CO 2017004994A2
Authority
CO
Colombia
Prior art keywords
diseases
disorders
urea analogs
sirtuin modulators
sirtuin
Prior art date
Application number
CONC2017/0004994A
Other languages
English (en)
Inventor
William Henry Miller
Ryan Michael Fox
James Lamond Ellis
Karen Anderson Evans
Mark Andrew Seefeld
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CO2017004994A2 publication Critical patent/CO2017004994A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos análogos de urea unidos sustituidos de Fórmula (I) o sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas correspondientes, procesos para preparar y usar dichos compuestos, solos o en combinación con otros agentes terapéuticos, como Moduladores de Sirtuina útiles para aumentar la longevidad de una célula, y en el tratamiento y/o la prevención de una amplia diversidad de enfermedades y trastornos, que incluyen, pero sin limitación, por ejemplo, enfermedades o trastornos relacionados con el envejecimiento o la tensión, diabetes, obesidad, enfermedades neurodegenerativas, enfermedad cardiovascular, trastornos de la coagulación sanguínea, inflamación, cáncer y/o enrojecimiento así como enfermedades o trastornos que se beneficiarían de la actividad mitocondrial aumentada.
CONC2017/0004994A 2014-11-19 2017-05-19 Análogos de urea unidos sustituidos como moduladores de sirtuina CO2017004994A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
PCT/IB2015/058978 WO2016079710A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
CO2017004994A2 true CO2017004994A2 (es) 2017-09-20

Family

ID=54705247

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004994A CO2017004994A2 (es) 2014-11-19 2017-05-19 Análogos de urea unidos sustituidos como moduladores de sirtuina

Country Status (21)

Country Link
US (4) US10072011B2 (es)
EP (4) EP3220918A1 (es)
JP (4) JP6806679B2 (es)
KR (4) KR20170083133A (es)
CN (4) CN107207521A (es)
AU (4) AU2015348942B2 (es)
BR (4) BR112017010602A2 (es)
CA (4) CA2968027A1 (es)
CL (1) CL2017001275A1 (es)
CO (1) CO2017004994A2 (es)
CR (1) CR20170209A (es)
DO (1) DOP2017000123A (es)
EA (1) EA201791074A1 (es)
ES (1) ES2823748T3 (es)
IL (1) IL252252A0 (es)
MX (1) MX2017006658A (es)
PE (1) PE20171257A1 (es)
PH (1) PH12017500913A1 (es)
RU (3) RU2017120857A (es)
SG (1) SG11201703824QA (es)
WO (4) WO2016079712A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) * 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
KR20220056223A (ko) * 2019-09-02 2022-05-04 메르크 파텐트 게엠베하 유기 전계발광 디바이스용 재료
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
KR20120092141A (ko) * 2009-10-29 2012-08-20 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 비시클릭 피리딘 및 유사체
AU2012352442A1 (en) * 2011-12-12 2014-07-03 Smb Innovation Aps Novel heterocyclic compounds useful in sirtuin binding and modulation
EP2997029B1 (en) * 2013-05-13 2019-01-09 GlaxoSmithKline LLC Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
EP3221317A1 (en) 2017-09-27
CA2968027A1 (en) 2016-05-26
BR112017010599A2 (pt) 2017-12-26
JP2017534664A (ja) 2017-11-24
EP3221317B1 (en) 2020-07-22
BR112017010602A2 (pt) 2017-12-26
KR20170087907A (ko) 2017-07-31
EP3221316A1 (en) 2017-09-27
CA2968029A1 (en) 2016-05-26
US10072011B2 (en) 2018-09-11
CN107108627A (zh) 2017-08-29
CN107207520A (zh) 2017-09-26
US20180319810A1 (en) 2018-11-08
KR20170083133A (ko) 2017-07-17
RU2017120857A (ru) 2018-12-19
MX2017006658A (es) 2018-01-15
CR20170209A (es) 2017-07-17
CA2968030A1 (en) 2016-05-26
WO2016079712A1 (en) 2016-05-26
JP2017534663A (ja) 2017-11-24
AU2015348944A1 (en) 2017-06-01
BR112017010601A2 (pt) 2017-12-26
EA201791074A1 (ru) 2017-10-31
PE20171257A1 (es) 2017-08-28
CN107207521A (zh) 2017-09-26
CN107207509A (zh) 2017-09-26
AU2015348942B2 (en) 2018-07-05
CA2968032A1 (en) 2016-05-26
AU2015348942A1 (en) 2017-06-01
JP2017534662A (ja) 2017-11-24
EP3221322A1 (en) 2017-09-27
JP6806679B2 (ja) 2021-01-06
KR20170083135A (ko) 2017-07-17
US20190048016A1 (en) 2019-02-14
US20170362234A1 (en) 2017-12-21
KR20170083134A (ko) 2017-07-17
WO2016079711A1 (en) 2016-05-26
CL2017001275A1 (es) 2017-12-15
IL252252A0 (en) 2017-07-31
ES2823748T3 (es) 2021-05-10
DOP2017000123A (es) 2017-08-15
RU2017120858A (ru) 2018-12-19
AU2015348943A1 (en) 2017-06-01
CN107207509B (zh) 2020-04-21
RU2017120855A (ru) 2018-12-19
WO2016079709A1 (en) 2016-05-26
WO2016079710A1 (en) 2016-05-26
EP3220918A1 (en) 2017-09-27
BR112017010595A2 (pt) 2018-01-02
PH12017500913A1 (en) 2017-12-04
AU2015348941A1 (en) 2017-06-01
US20170355705A1 (en) 2017-12-14
SG11201703824QA (en) 2017-06-29
JP2017534665A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
CO2017004994A2 (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
PE20151067A1 (es) Inhibidores de autotaxina
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
AU2014265671A8 (en) Substituted bridged urea analogs as sirtuin modulators
CO6400181A2 (es) Compuestos de tiazolopiridina moduladores de sirtuina
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
BR112013028665A2 (pt) compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CU20130094A7 (es) Moduladores de la vía del complemento
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
PE20150887A1 (es) Compuestos de benceno sustituidos
CO6741217A2 (es) Modulares de receptor de glucagón
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20140553A (es) Compuestos de fenoxietil piperidina
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
GT201400242A (es) "nuevos compuestos de pirazol"
UY35158A (es) ?moduladores selectivos del receptor de andrógenos novedosos?.
CL2017002229A1 (es) Inhibidores de bace1.